Vyzkoušejte nový nástroj s podporou AI
Summon Research Assistant
BETA
Beam Therapeutics Announced Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones Said First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in H2 2022
Get full text
Newsletter
DCAS13-MEDIATED THERAPEUTIC RNA BASE EDITING FOR IN VIVO GENE THERAPY
Year of Publication 13.04.2021
Get full text
Patent